ADDEX, in an exclusive collaboration and license agreement with Merck & Co, has achieved a second preclinical milestone in its trials to find a treatment for Parkinson’s disease.

The collaboration is focused on developing an emerging type of drugs, called allosteric modulators, for treatment of Parkinson’s disease and other undisclosed indications.

The collaboration focuses on developing drugs that activate the metabotropic glutamate receptor 4 (mGluR4).

The preclinical study showed the desired non-dopaminergic activity profile after oral administration of mGluR4 positive allosteric modulator in an animal model of Parkinson’s disease.

Addex head of the CNS business unit Emmanuel Le Poul said that both teams have worked together to achieve these successful results.

“We are pleased that these preclinical data show such promise in the animal model used. This work is a further validation of the target and the strength of our collaboration, as both teams have contributed to this achievement,” Le Poul said.